secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q/C TECHNOLOGIES, INC. (QCLS)
CIK:        0001321834
Form:       8-K
Filed at:   2024-10-07T23:59:59+00:00
Accession:  0001493152-24-040276
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TNF Pharma raises $600k via private placement at 20% premium; CRO partner engaged
--------------------------------------------------------------------------------

- Sold 283,019 shares at $2.12/share (120% of 30-day VWAP) to Prevail Partners, gross proceeds $600k.
- Proceeds for working capital; may be used to pay Prevail InfoWorks invoices under an August 2024 services agreement.
- Prevail InfoWorks engaged as CRO for upcoming Phase 2 sarcopenia/frailty study of MYMD-1 TNFα inhibitor.
- Press release states company is fully funded for clinical trials for next two years.
- MYMD-1 previously met primary endpoints in a small Phase 2 sarcopenia study (2023) reducing chronic inflammatory markers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1321834/000149315224040276/0001493152-24-040276-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1321834/000149315224040276/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-040276

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer